Circle Wealth Management LLC Takes $425,000 Position in Humana Inc. $HUM

Key Points

• Circle Wealth Management LLC has acquired a new stake in Humana Inc., purchasing 1,607 shares valued at approximately $425,000 during the 1st quarter.
• Institutional investors hold 92.38% of Humana's stock, with key investors like Vanguard Group and Pzena Investment Management increasing their positions significantly.
• Humana's recent quarterly earnings report showed a EPS of $6.27, missing estimates, but revenue rose 9.6% year-over-year, with a forecast of 16.47 EPS for the current year.

Circle Wealth Management LLC bought a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 1,607 shares of the insurance provider's stock, valued at approximately $425,000.

Other large investors have also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC raised its stake in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after purchasing an additional 46 shares during the last quarter. Riverview Trust Co acquired a new position in shares of Humana in the 1st quarter valued at $34,000. Garde Capital Inc. acquired a new stake in shares of Humana during the 1st quarter worth about $36,000. Zions Bancorporation National Association UT acquired a new stake in shares of Humana during the 1st quarter worth about $37,000. Finally, Whipplewood Advisors LLC increased its position in shares of Humana by 639.1% during the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after purchasing an additional 147 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 0.5%

HUM stock traded down $1.57 during mid-day trading on Wednesday, hitting $297.30. 859,185 shares of the company were exchanged, compared to its average volume of 1,711,584. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market cap of $35.76 billion, a P/E ratio of 22.82, a P/E/G ratio of 1.75 and a beta of 0.44. The firm's 50 day simple moving average is $250.98 and its 200 day simple moving average is $253.78. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The business's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the business posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana's dividend payout ratio (DPR) is 27.17%.

Analysts Set New Price Targets

A number of brokerages have commented on HUM. Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a report on Thursday, May 1st. Truist Financial decreased their price objective on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Bank of America decreased their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a report on Tuesday, June 17th. Barclays set a $275.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Finally, Wells Fargo & Company reduced their target price on shares of Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a research note on Thursday, August 14th. Seven research analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the stock. Based on data from MarketBeat, Humana currently has a consensus rating of "Hold" and an average price target of $283.29.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.